Tumor-infiltrating lymphocyte (TIL) therapy has also been shown to have high efficacy rates as first-line therapy as well as in the post-PD-1 setting in phase II and phase III trials, but has not yet reached regulatory approval (Rohaan et al., 2022; Monberg et al., 2023). This evidence concerns the gene PDCD1 and neoplasm.